Drug Profile
Research programme: MET 1000 - Acologix
Alternative Names: MET-1000Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Acologix
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-metastases in USA
- 28 May 2005 Preclinical trials in Cancer metastases in USA (unspecified route)